An induced pluripotent stem cell (iPSC) is an adult cell such as a skin or blood cell that has been genetically programmed to revert back to a stem cell. It was originally thought that once a stem cell had differentiated into a more specialised cell, the process was not reversible. In 2007,…
—Dragon Con 2014 Everything Stem Cells Panel
Dragon Con 2014 Everything Stem Cells Panel
Michael Gilkey, the Marketing and Operations Manager for both the National Center for Regenerative Medicine and the Center for Stem Cell and Regenerative Medicine, discussed stem cell research and treatments in a panel at Dragon Con 2014. Michael talks about the different types of stem cells being used for treatments, progress that has been made in stem cell research, as well as why stem cells are so controversial.
STEM CELLS at DRAGON CON!
Attention to Canadians who follow my blog, especially those who live in the Edmonton area.
"Those interested in becoming a stem cell donor must be between the ages of 17 and 35-years-old, in good general health and willing to donate to any patient in need. For more information visit the Canadian Blood Services website."
Surgeons implanted retinal tissue created after reverting the patient’s own cells to ‘pluripotent’ state.
Almost three years after a Bay Area company shut down the world’s first clinical trial of a therapy using embryonic stem cells, another local company is reviving the therapy. On Wednesday, Asterias said it had gained regulatory permission to test whether the treatment, which is derived from human embryonic stem cells, helps heal patients with a different kind of spinal cord injury. Created by voters a decade ago, the California Institute for Regenerative Medicine is authorized to spend $3 billion on stem cell research, and its future rests on the results, including any potential therapies, that those scientists and companies develop. Clearing 1st hurdle after struggling for years to get permission to start a clinical trial, Geron abandoned it in November 2011, saying it couldn’t afford to continue. In the upcoming trial with 13 patients, Asterias hopes to show the treatment is not only safe, but can also aid recovery from paralysis - a point Geron never reached. In 2001, then-President George W. Bush limited federal tax dollars for embryonic stem cell research, a policy that President Obama overturned by executive order in 2009, and some states have placed their own restrictions on such research. ViaCyte, a privately held company in San Diego, said this month that it won regulatory permission to start the first test of an embryonic stem cell-derived therapy in patients with Type 1 diabetes.